Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News

  News Archive

MRC Technology, AstraZeneca Collaborate
Thursday, June 16, 2016
Companies launching an initiative to find new epigenetic drug targets in respiratory disease.

Protagen Announces CE Mark for its Proprietary Multilisa® BICD2 Test
Thursday, June 16, 2016
BICD2 is the first proprietary biomarker discovered by Protagen employing the SeroTag® technology platform, and provides significant added value to standard diagnostics for Systemic Sclerosis (SSc).

Diagnosing Systemic Infections Quickly, Reliably
Wednesday, June 15, 2016
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.

What Makes a Good Scientist?
Wednesday, June 15, 2016
It’s the journey, not just the destination that counts as a scientist when conducting research.

Blood Test That Detects Early Alzheimer’s Disease
Monday, June 13, 2016
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.

A New Approach to Chemical Synthesis
Thursday, June 09, 2016
Communesins, originally found in fungus, could hold potential as cancer drugs.

Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
Wednesday, June 08, 2016
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.

Ultragenyx, Takeda Enter Collaboration
Wednesday, June 08, 2016
Ultragenyx to license and develop one or more product candidates from Takeda.

BMS, MD Anderson Announce Immuno-Oncology Collaboration
Wednesday, June 08, 2016
Bristol-Myers Squibb and The University of Texas MD Anderson Cancer Center have announced a new clinical research collaboration to evaluate innovative strategies for the potential use of Bristol-Myers Squibb’s immuno-oncology (I-O) agents Opdivo (nivolumab) and Yervoy (ipilimumab) to treat early- and advanced-stage lung cancer patients.

<< 1 2 3 4 5 6 7 >>
Showing Results 11 - 20 of 4228
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!